Next Article in Journal
Improved Electron Efficiency of Zero-Valent Iron towards Cr(VI) Reduction after Sequestering in Al2O3 Microspheres
Next Article in Special Issue
Management of Female Genital Mutilation/Cutting-Related Obstetric Complications: A Training Evaluation
Previous Article in Journal
Essential Factors for a Healthy Microbiome: A Scoping Review
 
 
Article
Peer-Review Record

Mifepristone (RU-486®) as a Schedule IV Controlled Drug—Implications for a Misleading Drug Policy on Women’s Health Care

Int. J. Environ. Res. Public Health 2022, 19(14), 8363; https://doi.org/10.3390/ijerph19148363
by Yi-Ping Hsieh 1,†, Yun-Ju Wang 2,†, Ling-Yi Feng 3, Li-Tzy Wu 4 and Jih-Heng Li 3,*
Reviewer 1:
Reviewer 3:
Reviewer 4:
Int. J. Environ. Res. Public Health 2022, 19(14), 8363; https://doi.org/10.3390/ijerph19148363
Submission received: 9 May 2022 / Revised: 1 July 2022 / Accepted: 5 July 2022 / Published: 8 July 2022
(This article belongs to the Special Issue Women's Gynecological and Reproductive Health—Issues and Challenges)

Round 1

Reviewer 1 Report

The authors make a strong case for re-consideration and re-evaluation of the scheduling of Mifepristone from its current status as a Schedule IV drug because of its lack of potential for addiction.  The issues are well presented and documented.

One consideration would be to include a figure that represents a timeline of the associated legislation, specifically affecting Taiwan, but also enabling a comparison with other countries in terms of how they have dealt with this issue

Author Response

Please see attached file.

Author Response File: Author Response.pdf

Reviewer 2 Report

The article represents a general analysis of the use of mifepristone in the women population and their right to have access to the drug. It seems an article highlights the right of women without providing a scientific insight on the matter. It would have been valuable, as a public health journal to ascertain if there is a relationship between doing a field analysis with women of reproductive age and correlating it with the prescription of the drug. In summary, the manuscript has to contain more than a general argument to be accessed for publication in a scientific journal

Author Response

Please see attached file.

Author Response File: Author Response.pdf

Reviewer 3 Report

Authors can present the methodology of the research in a comprehensive manner. It is quite hard to indicate. Social stigma and health issues of it can be described firther with a descriptivev manner and it should be also highlighted. 

Author Response

Please see attached file.

Author Response File: Author Response.pdf

Reviewer 4 Report

I think the current manuscript is best presented as a commentary or a review article. The methodology of article inclusion, screening and critical appraisal is not clear. 

Author Response

Please see attached file.

Author Response File: Author Response.pdf

Round 2

Reviewer 2 Report

The manuscript was improved partially although it was difficult to read since the authors should have cleaned the file and just highlight the new text. There are several grammatical errors in the inserted text to correct. The new table was appreciated, but the discussion requires work

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 4 Report

Thank you for the revised manuscript. I have no further comment. 

Author Response

The authors thank the reviewer's encouragement.

Back to TopTop